Evidence map›Paper›PMID 42273701›Full record

ReviewFrontiers in immunology2026

The microbiome-inflammation-immune axis in oral squamous cell carcinoma: from mechanistic insights to therapeutic perspectives.

Zhongjun Wang, QingYuan Bian, Yue Chu, Wanyue Zhu, Ying Qin, Jiwei Zheng

Abstract readReview
In one paragraph

Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Zhongjun WangDepartment of Stomatology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, China.
QingYuan BianDepartment of Stomatology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, China.
Yue ChuDepartment of Stomatology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, China.
Wanyue ZhuDepartment of Stomatology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, China.
Ying QinDepartment of Stomatology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, China.
Jiwei ZhengDepartment of Stomatology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Oral squamous cell carcinoma, the most prevalent malignancy of the head and neck, presents ongoing challenges regarding its molecular mechanisms and clinical management. Current research largely focuses on isolated signaling pathways or specific immune responses, often overlooking the potential contributing role of the microbiota in tumorigenesis. This review proposes the "microbiome-inflammation-immune axis" as an interpretive working hypothesis to elucidate how dysbiosis and microbial interactions may activate host inflammatory responses, trigger pattern recognition receptors and signaling pathways, and remodel the immune microenvironment, thereby potentially facilitating oral cancer progression. Concurrently, this paper emphasizes clinical translation by critically compiling and evaluating relevant clinical analytical indicators-such as peripheral blood inflammatory markers and salivary microbial markers-from the fields of inflammation and microbiology. This provides multidimensional reference points for future disease diagnosis and treatment.

Indexed as

Carcinoma, Squamous CellInflammationMicrobiotaMouth NeoplasmsAnimalsDysbiosisHumansSignal TransductionTumor Microenvironmentbiomarkersimmunoregulationinflammationmicrobial dysbiosisoral microbiotaoral squamous cell carcinomatumor microenvironment

Identifiers

PMID42273701
PMCPMC13246698

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.